DiscoverAcademicCME PodcastThe Emerging Role of Activin Signaling Inhibitor Therapeutics to Improve Outcomes for Patients with PAH
The Emerging Role of Activin Signaling Inhibitor Therapeutics to Improve Outcomes for Patients with PAH

The Emerging Role of Activin Signaling Inhibitor Therapeutics to Improve Outcomes for Patients with PAH

Update: 2025-03-17
Share

Description

This activity was supported by an educational grant from Merck & Co., Inc.. Please go to  ⁠academiccme.com/EPCPAH and complete the evaluation to receive your CE/CME Credit. Credit is available through September 19, 2025.

Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

The Emerging Role of Activin Signaling Inhibitor Therapeutics to Improve Outcomes for Patients with PAH

The Emerging Role of Activin Signaling Inhibitor Therapeutics to Improve Outcomes for Patients with PAH

Patrick Hayes